Short answer
UroGen Pharma Ltd. (URGN) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $72M (up 199.2% year over year) with net income of −$14M.
Q2 2026 key financials · XBRL
- Revenue
- $72M
- +199.2% YoY · +42.2% QoQ
- Net income
- −$14M
- +71.3% YoY · +39.1% QoQ
- Operating margin
- 0.2%
- Gross margin
- 90.9%
- EPS (diluted)
- −$0.28
- +73.3% YoY · +40.4% QoQ
Source: XBRL data from the UroGen Pharma Ltd. (URGN) Q2 2026 10-Q on SEC EDGAR. USD.
UroGen Pharma Ltd. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, net income, or actual margin percentages provided
- Best and worst product-line performance not disclosed with quarterly numbers
- UGN-103 NDA submission remains targeted for third quarter 2026, potential FDA approval in 2027
- UGN-104 enrollment expected complete by end of 2026; UGN-501 Phase 1 expected fourth quarter 2026
Risk Factors
- Accumulated deficit $997.6M as of June 30, 2026, with continuing losses threatening funding for operations and debt service
- Pharmakon facility expanded to $250.0M, with $200.0M drawn at 8.25% fixed interest and restrictive covenants
- New 2026 Loan Agreement triggered by February 26, 2026 refinancing, creating collateral and accelerated-default exposure
- Zusduri commercialization remains near-term execution risk after U.S. launch in June 2025 and limited marketing experience
- Available liquidity included $108.0M cash and securities plus approximately $42.4M remaining ATM capacity at June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UroGen Pharma Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.